OR WAIT null SECS
Linda Stein Gold, MD, explains what new ADORING data reveal about tapinarof cream for atopic dermatitis across age cohorts.
New analyses from the ADORING 1 and ADORING 2 phase 3 trials continue to reinforce tapinarof cream, 1% (VTAMA) as a treatment option for atopic dermatitis across a broad range of patients, according to Linda Stein Gold, MD.1,2
In this segment of her HCPLive interview, Stein Gold, known for her role as director of Dermatology Clinical Research and division head of Dermatology at Henry Ford Health, Stein Gold highlighted some of the implications of her team’s findings on tapinarof cream 1%.
Stein Gold noted that regulatory benchmarks for treatment success have grown considerably more stringent over the course of her career. She explained that current US Food and Drug Administration (FDA) standards for clear or almost-clear skin, as measured by vIGA-AD, represent a high bar, while EASI 75 reflects a 75% improvement from baseline.
Given that most trial participants had disease severe enough to be candidates for systemic therapy, she said achieving these benchmarks with a once-daily, non-steroidal topical cream by week 8 represents a meaningful clinical result.
Stein Gold said clinicians have long relied on topical steroids as a short-term mainstay of atopic dermatitis therapy, despite the chronic nature of the disease. She emphasized the value of non-steroidal options that can be applied across multiple body surface areas, including the face, skin folds, and hands, to simplify treatment regimens and support longer-term disease control.
Looking ahead, Stein Gold pointed to tapinarof's expanding role across chronic inflammatory skin diseases, noting its existing approval down to age 2 in atopic dermatitis and its FDA approval in psoriasis. She anticipates non-steroidal options will increasingly limit steroid use in clinical practice.
However, she identified younger pediatric patients, including infants as young as 3 to 4 months, as a population in need of further study, calling it a key unmet need in atopic dermatitis care.
Disclosures for Stein Gold include AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB.
References
